Mayzent

Siponimod, the active ingredient in Mayzent, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as a tablet for oral use. It treats relapsing forms of multiple sclerosis and secondary progressive multiple sclerosis in adults.

GNH USA supplies Mayzent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mayzent acts on the sphingosine‑1‑phosphate receptor pathway to modify disease activity in multiple sclerosis.

Relapsing‑remitting multiple sclerosis: reduces annualized relapse rate and slows disability accumulation. Secondary progressive multiple sclerosis with active disease: delays worsening of disability. Active disease in multiple sclerosis: decreases inflammatory activity as shown by MRI lesion reduction.

Common Side Effects: - Headache: mild to moderate intensity. - Hypertension: elevated blood pressure requiring monitoring. - Elevated liver enzymes: transient increases in ALT/AST. - Lymphopenia: reduced lymphocyte count. - Nasopharyngitis: upper respiratory tract infection symptoms. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Severe infections: opportunistic infections requiring immediate medical attention. - Cardiac arrhythmia: conduction abnormalities, especially after first dose. - Macular edema: visual disturbances, ophthalmologic evaluation needed. - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe liver injury: jaundice or hepatic failure signs. - Malignancy: increased risk of certain cancers with long‑term use.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

Monitor lymphocyte count: check before start and periodically during treatment. Assess liver function: perform baseline and periodic ALT/AST tests. Screen cardiac conduction: obtain ECG prior to first dose. Avoid use in active infection: defer treatment until infection resolves. Pregnancy and breastfeeding: discuss risks; drug not recommended. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Siponimod may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Strong CYP2C9 inhibitors (e.g., fluconazole): may increase siponimod exposure. - CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy. - Concurrent S1P modulators: additive immunosuppression risk.

Moderate Interactions (Monitor Closely): - Live vaccines: should be avoided during therapy. - Beta‑blockers: may affect heart‑rate monitoring after first dose. - Antihypertensives: monitor blood pressure for additive effects.